"C88311"^^ . "660135"^^ . "MOMELOTINIBPTFDA6O01GMS00P" . . "6O01GMS00P"^^ . "660135"^^ . "MomelotinibPTNCI" . "JAK1/2 Inhibitor CYT387SYNCI" . "Momelotinib"^^ . "CL413566"^^ . "An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.NCI" . . "Momelotinib"^^ . "C23H22N6O2"^^ . . "N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamideSNNCI" . "CYT387CNNCI" . "Pharmacologic Substance"^^ . "1056634-68-4"^^ . "FDA"^^ .